News
CCCC
6.17
-1.12%
-0.07
Weekly Report: what happened at CCCC last week (0415-0419)?
Weekly Report · 6d ago
Weekly Report: what happened at CCCC last week (0408-0412)?
Weekly Report · 04/15 09:02
C4 Therapeutics Presents New Preclinical Data For CFT1946 Highlighting Superior Activity As A Single Agent To Clinically Approved BRAF Inhibitor Standard Of Care Combinations At The American Association For Cancer Research Annual Meeting 2024
C4 Therapeutics, Inc. Presented new preclinical data for CFT1946 at the American Association for Cancer Research's Annual Meeting 2024. The company's drug is the only BRAF V600X mutant-specific degrader in the clinic. CFT 1946 selectively degrades the BRAf V600x mutant protein.
Benzinga · 04/08 12:25
Weekly Report: what happened at CCCC last week (0401-0405)?
Weekly Report · 04/08 09:02
Weekly Report: what happened at CCCC last week (0325-0329)?
Weekly Report · 04/01 09:02
Weekly Report: what happened at CCCC last week (0318-0322)?
Weekly Report · 03/25 09:02
Weekly Report: what happened at CCCC last week (0311-0315)?
Weekly Report · 03/18 09:02
Weekly Report: what happened at CCCC last week (0304-0308)?
Weekly Report · 03/11 09:02
C4 Therapeutics Initiates Stock Option Repricing for Retention
TipRanks · 03/08 21:23
C4 Therapeutics To Present New Preclinical Data On Highly Selective Orally Bioavailable BiDAC Degraders At The American Association For Cancer Research Annual Meeting 2024
C4 Therapeutics, Inc. Accepted two preclinical poster presentations at the American Association for Cancer Research Annual Meeting 2024 in San Diego. The company is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science. C4T's CFT1946 is a BRAF V600X mutant-specific degrader.
Benzinga · 03/05 21:35
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
BUZZ-U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
U.S. Stocks were set for a muted open on Monday. Dow e-minis were down 0.51% in early trading. The S&P 500 and the Nasdaq's record-closing highs in the prior session. The top three NYSE percentage gainers were Avidity, C4 Therapeutics, Avadel Pharma.
Reuters · 03/04 14:29
BUZZ-C4 Therapeutics rises on license agreement with Merck KGaA
Shares of drug developer C4 Therapeutics rise 2.27% to $11.24 premarket. Co says it has entered into a license agreement with Merck KGaA to discover two drugs that target cancer causing proteins. C4 to receive an upfront payment of $16 million.
Reuters · 03/04 12:54
C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA
TipRanks · 03/04 12:22
Weekly Report: what happened at CCCC last week (0226-0301)?
Weekly Report · 03/04 09:02
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. However, C4's valuation appears high compared to its peers and the company has a "hold" rating.
Seeking Alpha · 03/01 21:10
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
C4 Therapeutics, Inc. (NASDAQ:CCCC) has seen its share price rise 51% to US$10.95 in the last 7 days. The analysts have upgraded their near-term forecasts for the company's revenues and earnings per share. The most recent consensus is for revenues of US$25m in 2024 - a 21% increase on the previous year. Analysts have also increased their price target for the stock to US $16.89 on the back of the upgrade.
Simply Wall St · 02/29 11:14
Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
C4 Therapeutics is a biopharmaceutical company advancing targeted protein degradation science. The company has a 12-month average price target of $9.75. The firm has a positive revenue growth rate of 63.93% over the last three months. C4Therapeutics has an average of 4 analysts' evaluations of the company. Four analysts have raised their ratings and price targets for the company in the last month.
Benzinga · 02/26 16:00
C4 Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 02/26 15:52
C4 Therapeutics Price Target Raised to $8.00/Share From $1.00 by Morgan Stanley
Dow Jones · 02/26 15:52
More
Webull provides a variety of real-time CCCC stock news. You can receive the latest news about C4 Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.